3.Metformin has a long track record of efficacy, minimal weight gain and low risk of hypoglycemia. Despite the potential benefits of metformin, some patients cannot tolerate the gastroin-testinal (GI) side effects associated with this drug [3].Insulin secretagogues, such as sulfonylureas and megli-
tinides, are also frequently used early in the treatment of a patient with diabetes as they generally elicit clinical efficacy in the short term; however, they have been noted to fail to maintain efficacy over time. While the secretagogues are targeting one of the component defects of T2DM by stimulating endogenous insulin secretion, they are often associated with hypoglycemia and weight gain, thus limiting their use. Thiazolidinediones target a third aspect of the physiologic defects of the diabetic patient by increasing insulin sensitivity in the periphery and have shown sustained durability of effect and infrequent incidence of hypoglycemia; however, they, too, have side effects that possibly limit their use, such as edema and weight gain
你用什么烦的?好快啊 !